Lutetium (177Lu) Zadavotide Guraxetan

6 trials 3 recruiting VVarious

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

2 Completed trials

5 Sponsors

7 Countries

Phase III

Phase II

Phase I (FiH)

Phase III: 2 Phase II: 3 Phase I (FiH): 1

Indications tested

Hormone-refractory prostate cancer 1 Prostate cancer recurrent 1

Sponsors using this IMP

Medical University Of Vienna 2 Amsterdam UMC Stichting 1 Curium Pet France 1 Norwegian University Of Science And Technolology 1 UZ Leuven 1

All trials

6 total

68Ga/177Lu-PSMA theranostics in recurrent grade 3 and grade 4 glioma Pending

2024-518495-31-00 Phase II 1 country Norwegian University Of Science And Technolology
Neoadjuvant [177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA… Recruiting

2024-519377-18-00 Phase II 1 country Medical University Of Vienna
[177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with prostate cancer and biochemical but not radio-morphological local recurre… Recruiting

2024-519348-34-00 Phase II 1 country Medical University Of Vienna
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting

2022-502254-13-00 Phase III 1 country UZ Leuven
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patie… Ended

2022-501493-19-00 Phase III 3 countries Curium Pet France
DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTA… Ended

2024-518985-29-02 Phase I (FiH) 1 country Amsterdam UMC Stichting

Showing 1–6 of 6 trials

← All drugs A–Z